ERAS - Erasca

-

$undefined

N/A

(N/A)

Erasca NasdaqGS:ERAS Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Location: 3115 Merryfield Row, San Diego, CA, 92121, United States | Website: https://www.erasca.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

157M

Cash

304.6M

Avg Qtr Burn

-26.93M

Short % of Float

10.58%

Insider Ownership

12.37%

Institutional Own.

84.49%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Naporafenib (pan-RAF inhibitor) w/ trametinib Details
Solid tumor/s, RAS Q61X solid tumors

Phase 1b

Update

ERAS-007 w/ encorafenib and cetuximab Details
Cancer, Advanced malignancies, Gastrointestinal stromal tumors, Colorectal cancer , BRAFm Colorectal Cancer

Phase 1b

Update

Phase 1

Data readout

ERAS-0015 Details
RAS-mutant (RASm) solid tumors

Phase 1

Initiation

ERAS-601 (SHP2 inhibitor) Details
Solid tumor/s, Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

ERAS-007 Details
Non-small cell lung carcinoma

Failed

Discontinued

ERAS-007 + ERAS-601 Details
Solid tumor/s, Cancer

Failed

Discontinued